Novavax, Inc. announced that its partners secured regulatory clearance for the XFG-adapted Nuvaxovid vaccine in the United States, European Union and Japan. Shares dipped 0.6% to $9.00 as of 11:58 a.m. EDT.
Regulatory clearance is complete; royalties now depend on partner-led demand.
| Revenue channel | Economics | What changed |
|---|---|---|
| Sanofi royalties | High teens–low 20s % of global net sales | U.S. and EU seasonal approvals enable sales |
| Takeda | Royalties plus annual approval milestones | Japan approval supports 2026–2027 season |
| Sanofi supply | Recorded as product sales | Commercial supply planned this season |
| Technology transfer | $75M potential milestone | Expected mid-2027 |
Excludes Sanofi supply sales, royalties and milestones.
Versus $751M at Dec. 31, 2025
| Q2 2026 | Value | Year-over-year |
|---|---|---|
| Total revenue | $57M | −76% |
| Product sales | $19M | +76% |
| Net loss | $53M | vs. $107M profit |
| Net R&D expense | $48M | −34% |
| SG&A expense | $27M | −39% |
+47% from $9.00
| High | $19.00 |
| Low | $7.00 |
| Ratings | 2 Buy · 1 Hold · 1 Sell |
Approvals remove regulatory risk, but the stock's muted reaction signals demand uncertainty. The core sensitivities are vaccine uptake, coverage policy, Sanofi execution and timing of royalty recognition. Management gives no Sanofi sales forecast.
Sources: Novavax Aug. 28 approval update and Aug. 6 financial results; Reuters Aug. 27 FDA report; Google Finance. Prices are delayed U.S. quotes at 11:58 EDT on Aug. 28, 2026.
Not apples-to-apples: fund reports cover older quarters. Insider purchases occurred August 5–12. Share counts show scale, not current market direction.
The hold-heavy mix fits the narrow upside to the average target.
Operational growth. Guidance midpoint rose by $500 million after Q2.
Cash yield plus newer medicines. The indicated dividend yield remains above 6%. Launched and acquired products grew 18% operationally, and management raised the revenue midpoint.
The bridge beyond 2028. Falling COVID sales, patent losses and $4.3 billion of Q2 impairments keep attention on oncology, obesity assets and cost execution.
